Close Menu
Home » Pocketing $68M, PacBio Remains on Track for Commercial Launch — and Possible IPO — in 2010

Pocketing $68M, PacBio Remains on Track for Commercial Launch — and Possible IPO — in 2010

Aug 18, 2009
Premium

By Bernadette Toner

This article has been updated from a version posted on Aug. 13 to include additional information about the current financing environment for sequencing technology startups.

Pacific Biosciences said last week that it has raised $68 million in financing from a combination of new and existing investors, bringing its total VC financing to more than $260 million since it was founded in 2004.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Variant Linked to Heart Failure Risk

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

Gene Editing for the Gold

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

A Different Future

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

Nature Examines Lifespans, Fast and Accurate Method for Long-Read Assembly, More

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

What's Popular?

In Clinical Sequencing

  1. At ASH, Researchers Discuss Rapid AML Nanopore Sequencing Assay for Analyzing Actionable Alterations

  2. Online Tool to Select Secondary Findings May Shorten Genetic Counseling Sessions

  3. Gene Panel Finds Pathogenic Variants Missed by Standard Tests in 5 Percent of Familial Cancer Cases

  4. Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

  5. ASH Study: Germline Testing Identifies Cancer Risk Mutations, VUS in Older AML Patients

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.